Literature DB >> 32563549

Optimising Medications for Patients With Cancer and Multimorbidity: The Case for Deprescribing.

J P Turner1, K Kantilal3, K Kantilal3, H M Holmes4, B Koczwara5.   

Abstract

The majority of patients diagnosed with cancer are aged over 65 years and have two or more chronic conditions in addition to cancer and the risk of chronic conditions increases further after cancer. The presence of multimorbidity adds complexity to care, as patients' goals of care and the focus of treatment can change with a diagnosis of cancer. Multimorbidity is frequently associated with polypharmacy, the use of potentially inappropriate medications, the presence of adverse drug reactions and potential drug-drug interactions: all of which impact on health outcomes and the cost of care. Consequently, it is vital that a systematic approach is taken to regularly review cancer patients' medication regimens to ensure that they support an optimal balance of benefits with acceptable levels of harm. Several patient and clinician resources are presented to guide the process of medication review and deprescribing.
Copyright © 2020 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clinical oncology; deprescribing; multimorbidity and cancer; polypharmacy; potentially inappropriate medications

Mesh:

Year:  2020        PMID: 32563549     DOI: 10.1016/j.clon.2020.05.015

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  2 in total

1.  Research priorities to address polypharmacy in older adults with cancer.

Authors:  Ginah Nightingale; Mostafa R Mohamed; Holly M Holmes; Manvi Sharma; Erika Ramsdale; Grace Lu-Yao; Andrew Chapman
Journal:  J Geriatr Oncol       Date:  2021-02-13       Impact factor: 3.929

2.  Use of Non-Cancer Medications in New Zealand Women at the Diagnosis of Primary Invasive Breast Cancer: Prevalence, Associated Factors and Effects on Survival.

Authors:  Phyu Sin Aye; Oliver W Scott; J Mark Elwood; Diana Sarfati; Ross Lawrenson; Ian D Campbell; Marion Kuper-Hommel; Sandar Tin Tin
Journal:  Int J Environ Res Public Health       Date:  2020-10-29       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.